A phase 1b Study of Ruxolitinib in Combination with PU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF).

Administered By

Duke Cancer Institute

Awarded By

Samus Therapeutics, Inc.

Contributors

Arcasoy, Murat Osman Principal Investigator

Start/End

July 10, 2018 - October 22, 2021